Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo.

Haggag YA, Matchett KB, Falconer RA, Isreb M, Jones J, Faheem A, McCarron P, El-Tanani M.

Cancers (Basel). 2019 Feb 14;11(2). pii: E222. doi: 10.3390/cancers11020222.

2.

Intradermal Delivery of a Near-Infrared Photosensitizer Using Dissolving Microneedle Arrays.

Hamdan IMN, Tekko IA, Matchett KB, Arnaut LG, Silva CS, McCarthy HO, Donnelly RF.

J Pharm Sci. 2018 Sep;107(9):2439-2450. doi: 10.1016/j.xphs.2018.05.017. Epub 2018 Jun 1.

PMID:
29864428
3.

Advances in Precision Medicine: Tailoring Individualized Therapies.

Matchett KB, Lynam-Lennon N, Watson RW, Brown JAL.

Cancers (Basel). 2017 Oct 25;9(11). pii: E146. doi: 10.3390/cancers9110146.

4.

Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy.

Hay JF, Lappin K, Liberante F, Kettyle LM, Matchett KB, Thompson A, Mills KI.

Oncotarget. 2017 Jul 1;8(40):67891-67903. doi: 10.18632/oncotarget.18910. eCollection 2017 Sep 15.

5.

Erythropoietin drives breast cancer progression by activation of its receptor EPOR.

Chan KK, Matchett KB, Coulter JA, Yuen HF, McCrudden CM, Zhang SD, Irwin GW, Davidson MA, Rülicke T, Schober S, Hengst L, Jaekel H, Platt-Higgins A, Rudland PS, Mills KI, Maxwell P, El-Tanani M, Lappin TR.

Oncotarget. 2017 Jun 13;8(24):38251-38263. doi: 10.18632/oncotarget.16368.

6.

Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells.

Haggag YA, Matchett KB, Dakir el-H, Buchanan P, Osman MA, Elgizawy SA, El-Tanani M, Faheem AM, McCarron PA.

Int J Pharm. 2017 Apr 15;521(1-2):40-53. doi: 10.1016/j.ijpharm.2017.02.006. Epub 2017 Feb 2.

PMID:
28163220
7.

Big Data-Led Cancer Research, Application, and Insights.

Brown JA, Ni Chonghaile T, Matchett KB, Lynam-Lennon N, Kiely PA.

Cancer Res. 2016 Nov 1;76(21):6167-6170. Epub 2016 Oct 20.

8.

Ran GTPase promotes cancer progression via Met recepto-rmediated downstream signaling.

Yuen HF, Chan KK, Platt-Higgins A, Dakir el-H, Matchett KB, Haggag YA, Jithesh PV, Habib T, Faheem A, Dean FA, Morgan R, Rudland PS, El-Tanani M.

Oncotarget. 2016 Nov 15;7(46):75854-75864. doi: 10.18632/oncotarget.12420.

9.

Low-dose salinomycin induces anti-leukemic responses in AML and MLL.

Roulston GD, Burt CL, Kettyle LM, Matchett KB, Keenan HL, Mulgrew NM, Ramsey JM, Dougan C, McKiernan J, Grishagin IV, Mills KI, Thompson A.

Oncotarget. 2016 Nov 8;7(45):73448-73461. doi: 10.18632/oncotarget.11866.

10.

Resistance to HSP90 inhibition involving loss of MCL1 addiction.

Busacca S, Law EW, Powley IR, Proia DA, Sequeira M, Le Quesne J, Klabatsa A, Edwards JM, Matchett KB, Luo JL, Pringle JH, El-Tanani M, MacFarlane M, Fennell DA.

Oncogene. 2016 Mar 24;35(12):1483-92. doi: 10.1038/onc.2015.213. Epub 2015 Jun 22.

11.

Protein deregulation associated with breast cancer metastasis.

Chan KK, Matchett KB, McEnhill PM, Dakir el H, McMullin MF, El-Tanani Y, Patterson L, Faheem A, Rudland PS, McCarron PA, El-Tanani M.

Cytokine Growth Factor Rev. 2015 Aug;26(4):415-23. doi: 10.1016/j.cytogfr.2015.05.002. Epub 2015 May 31. Review.

PMID:
26088937
12.

Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation.

Maxwell P, Melendez-Rodríguez F, Matchett KB, Aragones J, Ben-Califa N, Jaekel H, Hengst L, Lindner H, Bernardini A, Brockmeier U, Fandrey J, Grunert F, Oster HS, Mittelman M, El-Tanani M, Thiersch M, Schneider Gasser EM, Gassmann M, Dangoor D, Cuthbert RJ, Irvine A, Jordan A, Lappin T, Thompson J, Neumann D.

Br J Haematol. 2015 Feb;168(3):429-42. doi: 10.1111/bjh.13133. Epub 2014 Oct 4.

PMID:
25283956
13.

Concise reviews: cancer stem cells: from concept to cure.

Matchett KB, Lappin TR.

Stem Cells. 2014 Oct;32(10):2563-70. doi: 10.1002/stem.1798. Review.

14.

BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability.

Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, Orr KS, Vohhodina J, Kavanagh JN, Madden AF, Powell A, Manti L, McDade SS, Park BH, Prise KM, McIntosh SA, Salto-Tellez M, Richard DJ, Elliott CT, Harkin DP.

Cancer Res. 2014 May 15;74(10):2773-2784. doi: 10.1158/0008-5472.CAN-13-2611. Epub 2014 Mar 17.

15.

Ran GTPase in nuclear envelope formation and cancer metastasis.

Matchett KB, McFarlane S, Hamilton SE, Eltuhamy YS, Davidson MA, Murray JT, Faheem AM, El-Tanani M.

Adv Exp Med Biol. 2014;773:323-51. doi: 10.1007/978-1-4899-8032-8_15. Review.

PMID:
24563355
16.

Molecular and clinicopathological markers of prognosis in breast cancer.

Boyle DP, McCourt CM, Matchett KB, Salto-Tellez M.

Expert Rev Mol Diagn. 2013 Jun;13(5):481-98. doi: 10.1586/erm.13.29.

PMID:
23782255

Supplemental Content

Loading ...
Support Center